KR100408626B1 - Pharmaceutical composition for inhibiting the activity of phosphodiesterase - Google Patents

Pharmaceutical composition for inhibiting the activity of phosphodiesterase Download PDF

Info

Publication number
KR100408626B1
KR100408626B1 KR1020030000616A KR20030000616A KR100408626B1 KR 100408626 B1 KR100408626 B1 KR 100408626B1 KR 1020030000616 A KR1020030000616 A KR 1020030000616A KR 20030000616 A KR20030000616 A KR 20030000616A KR 100408626 B1 KR100408626 B1 KR 100408626B1
Authority
KR
South Korea
Prior art keywords
phosphodiesterase
pharmaceutical composition
inhibiting
activity
pde
Prior art date
Application number
KR1020030000616A
Other languages
Korean (ko)
Inventor
Joong Myung Cho
Tae Gyu Lee
Seong Gu Noh
Yong Ho Jeon
Kwang Yeon Hwang
Jin Hwan Kim
Jong Seob Kim
Original Assignee
Crystalgenomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystalgenomics Inc filed Critical Crystalgenomics Inc
Priority to KR1020030000616A priority Critical patent/KR100408626B1/en
Application granted granted Critical
Publication of KR100408626B1 publication Critical patent/KR100408626B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE: Provided is a pharmaceutical composition for inhibiting the activity of phosphodiesterase(PDE) containing a compound of the formula(1). It is used for prevention and treatment of diseases, such as asthma, chronic respiratory disorder and atopic dermatitis, caused by overaction of PDE. CONSTITUTION: A pharmaceutical composition for prevention and treatment of asthma, chronic respiratory disorder and atopic dermatitis is characterized by containing, as an active ingredient, a compound of the formula(1), as defined in the specification or its pharmaceutically acceptable salt, and having phosphodiesterase(PDE) inhibiting activity.
KR1020030000616A 2003-01-06 2003-01-06 Pharmaceutical composition for inhibiting the activity of phosphodiesterase KR100408626B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020030000616A KR100408626B1 (en) 2003-01-06 2003-01-06 Pharmaceutical composition for inhibiting the activity of phosphodiesterase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020030000616A KR100408626B1 (en) 2003-01-06 2003-01-06 Pharmaceutical composition for inhibiting the activity of phosphodiesterase

Publications (1)

Publication Number Publication Date
KR100408626B1 true KR100408626B1 (en) 2003-12-11

Family

ID=37422831

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020030000616A KR100408626B1 (en) 2003-01-06 2003-01-06 Pharmaceutical composition for inhibiting the activity of phosphodiesterase

Country Status (1)

Country Link
KR (1) KR100408626B1 (en)

Similar Documents

Publication Publication Date Title
MX2008013836A (en) 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
UA90858C2 (en) Controlled-release formulations containing vardenafil
UA85708C2 (en) Benzoxazine-containing pharmaceutical combinations for treating respiratory tract diseases
MXPA04012965A (en) Viral inhibitors.
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
WO2002066480A3 (en) 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2005018557A3 (en) Substituted pyridinones
GB0112348D0 (en) Compounds
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
TNSN08478A1 (en) Pyrazolo [3,4-d] pyrimidine derivatives useful to treat respiratory disorders
TW200615266A (en) Organic compounds
WO2006011050A3 (en) Pyridine derivatives
WO2008005956A3 (en) Pyrrolotriazine kinase inhibitors
MXPA05001581A (en) Use of and some novel imidazopyridines.
TW200745136A (en) 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
HK1057899A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
HK1087702A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
EP1775283A4 (en) 3-aminobenamide compound and vanilloid receptor 1 (vr1) activity inhibitor
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
TW200510392A (en) Chemical compounds
WO2008079873A3 (en) Thiazolyl compounds useful as kinase inhibitors
TW200505452A (en) Chemical compounds
CY2462B1 (en) Cyclohexyl dihydrobenzofuranes.

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20081107

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee